Huaren Pharmaceutical Co., Ltd. (SHE:300110)

Market Cap	3.12B -18.5%
Revenue (ttm)	1.33B +6.2%
Net Income	-462.97M
EPS	-0.39
Shares Out	1.18B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,382,804
Open	2.550
Previous Close	2.620
Day's Range	2.550 - 2.660
52-Week Range	2.410 - 3.750
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Huaren Pharmaceutical

Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, ant...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,549
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300110

Financial Performance

In 2025, Huaren Pharmaceutical's revenue was 1.32 billion, a decrease of -2.34% compared to the previous year's 1.35 billion. Losses were -462.90 million, -66.17% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error